Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU. Avacta partnered with Medusa Healthcare (“Medusa”) to obtain regulatory approval for the AffiDX® antigen test for consumer self-testing and has now received the CE mark from a European Notified Body...

Avacta Group plc, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Calibre Scientific Inc. (“Calibre”), a global provider of life science products, for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK and European Economic Area (EEA)...

Avacta Group plc the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer^® and pre|CISION™ platforms, is pleased to announce that the MHRA has confirmed registration of Avacta’s AffiDX^® SARS-CoV-2 antigen lateral flow test allowing the Company to place the product on the market in the UK for professional use...

Avacta Group plc., the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce positive data from the clinical validation of its AffiDX® SARS-CoV-2 antigen lateral flow test. Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads....

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents...

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer^® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or ‘Kent’, variant, and the D614G variant, as well as the original strain....

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK. These data show excellent performance of the test in identifying patients with an infectious viral load and no false positive results. Avacta’s SARS-CoV-2 rapid antigen test has been developed to identify infectious individuals so that they can isolate promptly and reduce the spread of COVID-19....

Avacta Group plc, the developer of Affimer^® biotherapeutics and reagents, and Mologic Ltd has announced that they have entered into a commercial partnership to accelerate to market Avacta’s AffiDX™ SARS-CoV-2 lateral flow rapid antigen test. Avacta will also support antigen testing in low and middle income countries by providing access to Avacta’s spike antigen test through Mologic....

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) (NASDAQ: BRKR, “Bruker”) to evaluate the Affimer-based, bead assisted mass spectrometry (“BAMS™”) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc. (Beverley, MA) (“Adeptrix”)...

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples...

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the BAMS™ assay to detect the SARS-CoV-2 virus has been launched as a research kit by its partner Adeptrix (Beverly, MA, USA) and the assay has been presented by Bruker Scientific (Billerica, MA, USA), a leading mass spectrometer manufacturer, in a new application note...

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19. Enzyme linked immunosorbent assays (“ELISAs”) are very common research tools used to detect and quantify a target of interest in a wide range of samples....

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with the Liverpool School of Tropical Medicine (“LSTM”) to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva. LSTM has been at the forefront of research into infectious, debilitating and disabling diseases since 1898....

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in waste water, to provide a real-time alert system to warn of localised COVID-19 outbreaks...

Avacta Group plc, the developer of Affimer^® biotherapeutics and reagents, is pleased to announce that it has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (“BAMS™”) laboratory assay developed with Adeptrix. The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health Research...

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection. The World Health Organisation recently....

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays. Avacta and NEB have been collaborating to develop Affimers to combine with NEB’s reagents....

Drug conjugate combines Avacta’s Affimer technology with drug conjugates developed at Tufts. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, Professor of Developmental...

Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits. Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its research collaboration with FIT Biotech Oy (FITBIO:FN Finland) has successfully completed a proof-of-concept study...

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, are pleased to announce they have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse®. The research programme will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology....

Avacta Group plc is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully. 

Following this study the two companies have agreed the terms of a licensing deal which will allow them to develop drug conjugates using the combined technologies.  The detailed terms of the license have not been disclosed but Avacta would receive development milestone payments and royalties

Collaboration to assess the benefits of combining Affimer technology with FIT Biotech’s gtGTU platform

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and reagents, is pleased to announce it has initiated a research collaboration with FIT Biotech Oy (FITBIO:FN Finland) to assess the effectiveness of developing gene therapies using Avacta’s Affimer technology combined....

Important value inflection point validating commercial potential of Affimer technology and Company's business model

Avacta Group plc, the developer of Affimer^® biotherapeutics and research reagents, is pleased to report that an evaluation of the Affimer technology by a large, global diagnostics developer has concluded successfully and that the third party has taken exclusive rights to several Affimer reagents....

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and research reagents, is pleased to report that the first major immunogenicity study of Affimer technology using human ex-vivo samples has concluded successfully with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin^®.

Unwanted immunogenicity occurs when a patient has an immune response to a drug which can lead to reduced effectiveness of the drug and possibly lead to serious adverse side effects. It is therefore essential that a new drug platform, such as Affimer technology, is shown not to cause a significant intrinsic immunogenic response....

Appointment of Professor Gerard Evan further supports Affimer immuno-oncology therapeutics programme

Avacta Group plc, the developer of Affimer^® biotherapeutics and research reagents, has announced it has appointed Professor Gerard Evan, FRS, to its therapeutics Scientific Advisory Board. Professor Evan brings world-leading expertise in immuno-oncology and cancer stem cell research...

Avacta Group plc announces a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta’s Affimer technology in novel CAR-T cell-based immunotherapy.

CAR-T immunotherapy is a form of cancer treatment in which the patient’s own immune system T cells are modified to give them greater potency with which to attack cancer cells .Treatments using these engineered immune cells have generated promising responses in patients with advanced cancers and CAR-T immunotherapy has become an intense area of research, clinical development and investment.

Affimer PD-L1 inhibitor significantly reduces tumour growth in mouse model

Avacta Group plc, the developer of Affimer^® biotherapeutics and research reagents, is pleased to announce positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules. The results meaningfully de-risk the development of the technology as a therapeutic platform; demonstrating that Affimer molecules possess good drug-like properties in terms of efficacy, serum half-life and tolerability....

Expansion provides significant increase in laboratory space

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and research reagents, today announced it has opened two new facilities, in Cambridge and Wetherby, Yorkshire. The new buildings almost double the Company’s overall footprint, which increases from 9,500 to 18,500 sq ft, including new state-of-the-art laboratory facilities....

Collaboration to develop rapid tests to differentiate between viral and bacterial infections, and differentiate bacterial strains

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and research reagents, is pleased to announce that a collaborative development programme with Leeds University has been awarded a £3.8 million grant by the Medical Research Council to develop novel, rapid diagnostic tools incorporating Affimer reagents, to differentiate between viral and bacterial infections, and differentiate bacterial strains....

Avacta Group plc and Glythera Limited announce that they have established a collaboration to evaluate the use of Glythera’s PermaLink™ conjugation chemistry in combination with Avacta’s Affimer technology with the aim of developing a new class of highly targeted bio-therapeutics as a superior alternative to the established class of antibody drug conjugates (ADCs).

ADCs use an antibody to which a toxin/chemotherapy payload is chemically attached for targeted delivery to a tumour. Over 50 ADCs are currently in clinical development; of these, approximately a quarter are in Phase II or Phase III. The market is estimated to be worth around $1bn today from two approved compounds and is expected to be worth $10bn annually by 2024.

Avacta Group plc has announced it has identified three Affimer proteins capable of binding to a recombinant form of a secreted Zika virus NS1 protein (Non-Structural protein 1), which is diagnostic of Zika virus infection at the early, acute stage.

These Affimer binders were identified and characterised within just thirteen weeks of receiving the virus target and have the potential to be developed into new rapid point-of-care diagnostic tests for Zika infection.

Avacta’s Affimer technology will be used to develop rapid lateral flow diagnostics for clinical applications

Avacta Group plc (AIM: AVCT) the developer of Affimer^® biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, today announced they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point of care (POC) testing, using Avacta’s Affimer technology. As stated at the time of Avacta’s interim results, establishing commercial relationships in the POC testing market is one of the Company’s key strategic objectives....

Avacta’s Optim^® 2 platform is an innovative analytical instrument designed to probe multiple protein stability indicating parameters at high speed using ultra-low sample volumes.

Developed to reduce the time and cost of therapeutic protein preformulation studies, the functionality of this compact instrument family has now been further enhanced with the addition of two new models. The Optim 375 is intended for the investigation of complex mixtures of membrane proteins, using an additional 375 nm laser source to provide a novel stability screen based on the chemical reactivity of cysteine residues....

Avacta Life Sciences is investing £10m in the launch of Affimers, the engineered alternative to antibodies.